Phase 2 Eczema Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with chronic atopic dermatitis (a long-term skin condition also known as eczema) for at least 12 months before the first study visit
- People whose atopic dermatitis is rated as moderate or severe at the screening and baseline appointments, based on several standard skin assessment scores (confirm specific score thresholds with trial site)
- People whose skin condition has not responded well to standard topical treatments (such as steroid creams), or who have not been able to tolerate those treatments, within the past 6 months
- People who are using a plain, unfragranced moisturiser at least once a day
Who may not be able to join:
- People with ongoing or recurring health conditions that could interfere with the study medication or the way results are measured
- People with any illness or active infection that could affect their safety during the trial
- People with another skin condition, or large tattoos in affected areas, that could make it difficult for doctors to properly assess their skin
- People with a significant skin infection that requires treatment
- People whose blood or laboratory test results show clinically significant abnormal findings at the screening appointment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To evaluate the efficacy of ENV-294 compared to placebo on severity and extent of atopic dermatitis (AD)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.